Invion (ASX:IVX) secures services agreement with Pavay Biotech

03Feb

Invion (ASX:IVX) secures services agreement with Pavay Biotech

 

A subsidiary of Invion (ASX:IVX), EpiTech Dermal Science, has signed an R&D services agreement with a leading China-based pharmaceutical group in the skin repair and treatment market.

Under the agreement, EpiTech will be paid an upfront fee of $250,000 plus ongoing R&D services fees to manage the research, development and production specifications for the supply of dermatological ingredients.

The ingredients will be used in the formulation of dermatology products to be manufactured by Pavay Biotech.

The parties are still negotiating the manufacturing and supply agreement.

Shares in Invion (ASX:IVX) closed flat at 1.2 cents on Friday.
Copyright 2020 – Finance News Network


Source: Finance News Network

Share this post

Related Posts

24Jun

The Mirvac Group (ASX:MGR) reveals a reduction in value of properties

24 Jun 2020 - The Mirvac Group (ASX:MGR) today announced that its distribution for the year ending 30 June 2020 is 9.1 cents per stapled security.

Read More
11Jun

Kogan.com (ASX:KGN) completes $100 million institutional placement

11 Jun 2020 - Kogan.com (ASX:KGN) is pleased to announce the successful completion of its underwritten $100 million institutional placement at an offer price of $11.45 per new share.

Read More
27Nov

Stocks of the Hour: Tamboran Resources, RareX, Black Canyon

27 Nov 2023 - A snapshot of the stocks on the move, featuring Tamboran Resources (ASX:TBN), RareX (ASX:REE) and Black Canyon (ASX:BCA).

Read More
06Dec

Blackmores (ASX:BKL) appoint a new chief financial officer

06 Dec 2019 - Blackmores (ASX:BKL) today announced that Aaron Canning will transition from his current role as Chief Financial Officer next month, replaced by Gunther Burghardt.

Read More
20Nov

MACA (ASX:MLD) wins $480 Ravensthorpe contract

20 Nov 2019 - Contractor MACA (ASX:MLD) has received a letter of award from First Quantum Minerals for open pit mining services at the Ravensthorpe nickel project in southern Western Australia.

Read More
19Nov

Mayne Pharma (ASX:MYX) to extend range of dermatology products with licensing of $US40m drug

19 Nov 2019 - Mayne Pharma (ASX:MYX) will extend its range of dermatology products through the licensing of a generic topical dermatology product from Encube Ethicals which is a leading developer and manufacturer of topical formulations to distribute in the United States.

Read More
06Nov

Bubs (ASX:BUB) inks strategic agreement with Alibaba

06 Nov 2019 - Bubs Australia (ASX:BUB) has inked a strategic agreement with Alibaba Centralised Import Procurement to capitalise on the growth of China’s goat dairy market.

Read More
07Nov

Stocks of the Hour: Novatti Group, RareX, Altech Chemicals

07 Nov 2022 - A snapshot of the stocks on the move featuring Novatti Group (ASX:NOV), RareX (ASX:REE) and Altech Chemicals (ASX:ATC).

Read More
31Dec

ENN nominate new non-executive director

31 Dec 2020 - Santos (ASX:STO) reports that Yujiang (Eugene) Shi will be appointed to the Board as the ENN nominated non-executive director effective from today.

Read More
26Sep

Santos in another major Barossa contract award

26 Sep 2019 - Santos (ASX:STO) today announced the Barossa project has taken another big step towards a Final Investment Decision early next year with the award of the gas export pipeline contract.

Read More